Retraction: Sensitizing Estrogen Receptor–negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

Retraction: Sensitizing Estrogen Receptor–negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

This article (1) has been retracted at the request of the editors. Following institutional review by the Ohio State University it was determined that Fig. 4A and B were intentionally falsified by Dr. Ching-Shih Chen. The authors regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article. A copy of this Retraction Notice was sent to the last known email addresses for the authors. Three authors (S.K. Kulp, R.W. Brueggemeier, and C.L. Shapiro) agreed to the retraction; the four remaining authors (S-C. Weng, Y. Kashida, D. Wang, and C-S. Chen) could not be located.



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More